We Offer Worldwide Shipping
Login Wishlist

Alboctalol

$1,280

  • Brand : BIOFRON

  • Catalogue Number : BN-O1536

  • Specification : 98%(HPLC)

  • CAS number : 62394-00-7

  • Formula : C28H24O8

  • Molecular Weight : 488.5

  • PUBCHEM ID : 85235974

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1536

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

488.5

Appearance

Powder

Botanical Source

This product is isolated and purified from the herbs of Cudrania tricuspidata

Structure Type

Phenols

Category

Standards;Natural Pytochemical;API

SMILES

C1C(C(C(C2=C1C=C(C=C2O)O)C3=C(C=C(C=C3)O)O)C4=CC(=CC(=C4)O)O)C5=C(C=C(C=C5)O)O

Synonyms

(6S,7S,8R)-6,8-Bis(2,4-dihydroxyphenyl)-7-(3,5-dihydroxyphenyl)-5,6,7,8-tetrahydro-1,3-naphthalenediol/1,3-Naphthalenediol, 6,8-bis(2,4-dihydroxyphenyl)-7-(3,5-dihydroxyphenyl)-5,6,7,8-tetrahydro-, (6S,7S,8R)-/Alboctalol

IUPAC Name

6,8-bis(2,4-dihydroxyphenyl)-7-(3,5-dihydroxyphenyl)-5,6,7,8-tetrahydronaphthalene-1,3-diol

Density

1.5±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

345.1±27.5 °C

Boiling Point

779.0±60.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

QQGGCAFWTCETPD-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:62394-00-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30867954

Abstract

The title host compound, C62H84N4O4, designed to self-assemble to form a new type of extended core Piedfort unit reminiscent of an eight-legged spider host, forms a number of crystalline inclusion compounds favouring oxygen-containing guest mol­ecules. We have established the presence of this unit in the unsolvated mol­ecular crystal at 100 K, which is monoclinic, space group P21/n, with Z = 8. The new Piedfort unit is chiral and its core structure closely approximates to D 2 symmetry, with both enanti­omers present in the crystal. Rather than being superposed with a staggered arrangement of nitro­gen atoms, the rings are rotated by an angle of approximately 45° with respect to each other, and the shortest contact between them is 3.181 (2) a. The compound’s significant inclusion properties may be taken to suggest the participation of an extended Piedfort unit in the microcrystalline adducts formed. The presence of such a dimeric host unit in the clathrates has, however, not yet been established because of the current lack of suitable single crystals for X-ray analysis.

KEYWORDS

crystal structure, host-guest, inclusion, Piedfort, spider host, self-assembly

Title

Synthesis and crystal structure of 2,4,6,8-tetra­kis­(3,5-di-tert-butyl­phen­oxy)pyrimido[5,4-d]pyrimidine: expansion of the Piedfort concept

Author

James H. Gall,a David D. MacNicol,a Ross MacSween,a and Christopher S. Framptonb,*

Publish date

2019 Mar 1

PMID

31579144

Abstract

We propose using a modified amplification refractory mutation system real-time polymerase chain reaction (ARMS RTPCR) technique to exclude the invasive prenatal diagnosis for a non-paternally inherited beta thalassemia mutation in couples atrisk for having a baby with CHBT. The ARMS RT-PCR method was performed for 36 at-risk couples by using isolated fetal cell-free DNA from maternal plasma. The modified ARMS RT-PCR primers targeted one of the following paternally inherited beta thalassemia mutation: -28 A→G, CD17 A→T, CD 26 G→A, IVS1-1 G→T and CD 41-42 -CTTT. The method could be successfully employed for NIPST starting with the 7th week of gestation. The results showed that 19 pregnant women were negative for PIBTM (53%). After an on-track and on-time of one year, including postnatal thalassemia blood tests, none of the babies showed symptoms or signs of beta thalassemia disease. We concluded that the modified ARMS RT-PCR method was an accurate, cost-effective and feasible method for use as a NIPST for at-risk couples with the potential of having a baby with CHBT.

KEYWORDS

NIPST, ARMS RT-PCR, Maternal cell-free fetal DNA, Paternally inherited beta thalassemia mutation

Title

Noninvasive prenatal screening test for compound heterozygous beta thalassemia using an amplification refractory mutation system real-time polymerase chain reaction technique

Author

Narutchala Suwannakhon,1 Tanapat Pangeson,2 Teerapat Seeratanachot,2 Khwanruedee Mahingsa,3 Arunee Pingyod,3 Wanwipa Bumrungpakdee,3 and Torpong Sanguansermsri3

Publish date

2019 Sep 18

PMID

24022077

Abstract

Background:
Provisions of the Affordable Care Act that increase hospitals’ financial accountability for preventable readmissions have heightened interest in identifying system-level interventions to reduce readmissions.

Objectives:
To determine the relationship between hospital nursing; that is, nurse work environment, nurse staffing levels, and nurse education, and 30-day readmissions among Medicare patients with heart failure, acute myocardial infarction, and pneumonia.

Method and Design:
Analysis of linked data from California, New Jersey, and Pennsylvania that included information on the organization of hospital nursing (ie, work environment, patient-to-nurse ratios, and proportion of nurses holding a BSN degree) from a survey of nurses, as well as patient discharge data, and American Hospital Association Annual Survey data. Robust logistic regression was used to estimate the relationship between nursing factors and 30-day readmission.

Results:
Nearly 1 quarter of heart failure index admissions [23.3% (n = 39,954)], 19.1% (n=12,131) of myocardial infarction admissions, and 17.8% (n = 25,169) of pneumonia admissions were readmitted within 30 days. Each additional patient per nurse in the average nurse’s workload was associated with a 7% higher odds of readmission for heart failure [odds ratio (OR) = 1.07; confidence interval CI, 1.05-1.09], 6% for pneumonia patients (OR = 1.06; CI, 1.03-1.09), and 9% for myocardial infarction patients (OR = 1.09; CI, 1.05-1.13). Care in a hospital with a good versus poor work environment was associated with odds of readmission that were 7% lower for heart failure (OR = 0.93; CI, 0.89-0.97), 6% lower for myocardial infarction (OR = 0.94; CI, 0.88-0.98), and 10% lower for pneumonia (OR = 0.90; CI, 0.85-0.96) patients.

Conclusions:
Improving nurses’ work environments and staffing may be effective interventions for preventing readmissions.

KEYWORDS

nursing, readmissions, quality of health care, work environment, organizational culture

Title

Hospital Nursing and 30-Day Readmissions Among Medicare Patients With Heart Failure, Acute Myocardial Infarction, and Pneumonia

Author

Matthew D. McHugh, PhD, JD, MPH, RN and Chenjuan Ma, PhD, RN

Publish date

2019 Nov 5.


Description :

Empty ...